The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
Open accessAbstract
BACKGROUND: Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease. METHODS: We analyzed three independent cohorts that included a total of 455 patients with hepatocellular carcinoma who had undergone radical tumor resection between 1999 and 2003. MicroRNA-expression profiling was performed in a cohort of 241 patients with hepatocellular carcinoma to identify tumor-related microRNAs and determine their association with survival in men and women. In addition, to validate our findings, we used quantitative reverse-transcriptase-polymerase-chain-reaction assays to measure microRNAs and assess their association with survival and response to therapy with interferon alfa in 214 patients from two independent, prospective, randomized, controlled trials of adjuvant interferon therapy. RESULTS: In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. Tumors had reduced levels of miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of miR-26 expression was also associated with hepatocellular carcinoma. Moreover, tumors with reduced miR-26 expression had a distinct transcriptomic pattern, and analyses of gene networks revealed that activation of signaling pathways between nuclear factor kappaB and interleukin-6 might play a role in tumor development. Patients whose tumors had low miR-26 expression had shorter overall survival but a better response to interferon therapy than did patients whose tumors had high expression of the microRNA. CONCLUSIONS: The expression patterns of microRNAs in liver tissue differ between men and women with hepatocellular carcinoma. The miR-26 expression status of such patients is associated with survival and response to adjuvant therapy with interferon alfa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023
Self-citationA MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia
Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050995 · Cited by 2,403
Self-citationGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
MicroRNA profiling: approaches and considerations
Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3198 · Cited by 1,765
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Self-citationMicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Mechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Roessler, S., Jia, H.-L., Budhu, A., Forgues, M., Ye, Q.-H., Lee, J.-S., Thorgeirsson, S. S., Sun, Z., Tang, Z.-Y., Qin, L.-X., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2607 · Cited by 1,044
Self-citationMicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Self-citationHou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.001 · Cited by 690
Self-citationInflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Biological functions of microRNAs: a review
Huang, Y., Shen, X. J., Zou, Q., Wang, S. P., Tang, S. M., & Zhang, G. Z. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-010-0050-6 · Cited by 652
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Self-citationmicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer
Braconi, C., Kogure, T., Valeri, N., Huang, N., Nuovo, G., Costinean, S., Negrini, M., Miotto, E., Croce, C. M., & Patel, T. (2011) · Oncogene · doi:10.1038/onc.2011.193 · Cited by 642
Self-citationPlasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J., Dai, Z., Wang, J.-F., Zhang, Z., Lu, S., Huang, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2697 · Cited by 635
Self-citationWang, Y., He, L., Du, Y., Zhu, P., Huang, G., Luo, J., Yan, X., Ye, B., Li, C., Xia, P., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.03.003 · Cited by 634
Yang, F., Zhang, L., Huo, X.-S., Yuan, J.-H., Xu, D., Yuan, S.-X., Zhu, N., Zhou, W.-P., Yang, G.-S., Wang, Y.-Z., et al. (2011) · Hepatology · doi:10.1002/hep.24563 · Cited by 632
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Szabo, G., & Bala, S. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.87 · Cited by 588
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Cancer stem cells in the development of liver cancer
Yamashita, T., & Wang, X. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66024 · Cited by 525
Self-citationMicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Self-citationGuidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citationHe, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S. E., Jepsen, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.031 · Cited by 474
Fang, Y., Xue, J.-L., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425
Shen, Q., Fan, J., Yang, X.-R., Tan, Y., Zhao, W., Xu, Y., Wang, N., Niu, Y., Wu, Z., Zhou, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70233-4 · Cited by 394
Self-citationLu, J., He, M.-L., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y.-C., Peng, Y., Yao, K.-T., Kung, H.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1850 · Cited by 381
Self-citationDi Leva, G., & Croce, C. M. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.01.004 · Cited by 356
Self-citationMicroRNAs: New Tools for Diagnosis, Prognosis, and Therapy in Hepatocellular Carcinoma?
Giordano, S., & Columbano, A. (2013) · Hepatology · doi:10.1002/hep.26095 · Cited by 354
Reprogramming of miRNA networks in cancer and leukemia
Volinia, S., Galasso, M., Costinean, S., Tagliavini, L., Gamberoni, G., Drusco, A., Marchesini, J., Mascellani, N., Sana, M. E., Abu Jarour, R., et al. (2010) · Genome Research · doi:10.1101/gr.098046.109 · Cited by 349
Self-citationRoessler, S., Long, E. L., Budhu, A., Chen, Y., Zhao, X., Ji, J., Walker, R., Jia, H., Ye, Q., Qin, L., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.039 · Cited by 319
Self-citationDysregulation of microRNAs in cancer: Playing with fire
Melo, S. A., & Esteller, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.08.009 · Cited by 315
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis
Liu, N., Chen, N.-Y., Cui, R.-X., Li, W.-F., Li, Y., Wei, R.-R., Zhang, M.-Y., Sun, Y., Huang, B.-J., Chen, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70102-x · Cited by 293
Yang, X., Liang, L., Zhang, X.-F., Jia, H.-L., Qin, Y., Zhu, X.-C., Gao, X.-M., Qiao, P., Zheng, Y., Sheng, Y.-Y., et al. (2013) · Hepatology · doi:10.1002/hep.26305 · Cited by 280
Self-citationWang, X. W., Heegaard, N. H. H., & Ørum, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.007 · Cited by 280
Self-citationMicromarkers: miRNAs in cancer diagnosis and prognosis
Ferracin, M., Veronese, A., & Negrini, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.11 · Cited by 266
Oishi, N., Kumar, M. R., Roessler, S., Ji, J., Forgues, M., Budhu, A., Zhao, X., Andersen, J. B., Ye, Q.-H., Jia, H.-L., et al. (2012) · Hepatology · doi:10.1002/hep.25890 · Cited by 260
Self-citationThe Inflammation and Liver Cancer
Bishayee, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_16 · Cited by 255
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.009 · Cited by 232
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Zhu, X., Yuan, J., Zhu, T., Li, Y., & Cheng, X. (2016) · The FEBS Journal · doi:10.1111/febs.13839 · Cited by 143
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
miR‐338‐3p suppresses invasion of liver cancer cell by targeting smoothened
Huang, X., Chen, J., Wang, Q., Chen, X., Wen, L., Chen, L., Bi, J., Zhang, L., Su, Q., & Zeng, W. (2011) · The Journal of Pathology · doi:10.1002/path.2877 · Cited by 118
Liu, W.-T., Jing, Y.-Y., Gao, L., Li, R., Yang, X., Pan, X.-R., Yang, Y., Meng, Y., Hou, X.-J., Zhao, Q.-D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0340-7 · Cited by 63
Huang, Q., Yang, J., Zheng, J., Hsueh, C., Guo, Y., & Zhou, L. (2018) · Oncology Reports · doi:10.3892/or.2018.6672 · Cited by 19
Metadata
- Authors
- Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., Ambs, S., Chen, Y., Meltzer, P. S., Croce, C. M., Qin, L.-X., Man, K., Lo, C.-M., Lee, J., Ng, I. O. L., Fan, J., Tang, Z.-Y., Sun, H.-C., & Wang, X. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-08
- Volume
- 361
- Issue
- 15
- Pages
- 1437-1447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2065543285
- Cited by
- 802
- References
- 23
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.